Human medicines European public assessment report (EPAR): Eydenzelt, aflibercept, Date of authorisation: 12/02/2025, Revision: 2, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Piqray, Alpelisib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0090/2024
Human medicines European public assessment report (EPAR): Zyprexa, olanzapine, Date of authorisation: 27/09/1996, Revision: 46, Status: Authorised
Executive Steering Group on Shortages and Safety of Medicinal Products
Human medicines European public assessment report (EPAR): HBVaxPro, hepatitis B vaccine (recombinant DNA), Date of authorisation: 27/04/2001, Revision: 34, Status: Authorised
Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) annual activity report 2024
On-boarding of users to Substance, Product, Organisation and Referentials (SPOR) data services
Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0099/2024
Opinion/decision on a Paediatric investigation plan (PIP): Supemtek Tetra (previously Supemtek), recombinant Influenza Hemagglutinin-strain A (H1N1 subtype),recombinant Influenza Hemagglutinin-strain A (H3N2 subtype),recombinant Influenza Hemagglutinin-strain B (Victoria lineage),recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) (RIV4), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0098/2024
EMEA-003220-PIP01-22-M01